Tacoma, WA (PRWEB) November 11, 2011
Revalesio Corporation is presenting pre-clinical data at the American Heart Association (AHA) Scientific Sessions demonstrating that RNS60 may have beneficial effects on cardiac damage associated with heart attacks. The AHA Scientific Sessions are the preeminent cardiovascular meeting for researchers and clinicians and is being held November 12-16 in Orlando, Florida.
In this pilot, pre-clinical ischemia/reperfusion pig model of heart attacks, RNS60 reduced the mortality and reduced signs of heart tissue damage and overall inflammation in male pigs. In both male and female pigs, RNS60 lowered troponin levels (a marker of heart damage) and normalized ECG (electrocardiogram) tracings. Data from this study will be presented via poster session (#17400) on November 14th.. These results indicate that RNS60 may have promise in the treatment of reperfusion injury following a heart attack.
In addition to the data being presented at the AHA meeting, Revalesio has successfully completed a first-in-man clinical trial of RNS60 using intravenous (I.V.) dosing as a first step in evaluating the use of RNS60 for the treatment of acute myocardial infarctions (AMI/heart attacks). The study, conducted in conjunction with Quintiles in Overland Park, Kansas, met all safety endpoints and supports the unparalleled safety profile of RNS60.
This data indicates RNS60 may provide an important new treatment option for patients suffering from AMI. Further research of RNS60 is being conducted in pre-clinical models and a Phase II clinical trial in patients suffering from AMI is in development for 2012.
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines, chemokines resulting in decreased inflammation and cell death. RNS60 contains charge-stabilized nanostructures (CSN) that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.
About Revalesio Corporation
Revalesio is a pioneering clinical stage biomedical company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuro-inflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.